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ABSTRACT
A series of polyphenolic-sulfonated compounds were observed to have potent anti-inflammatory activity
and were protective against induced endotoxic shock in mice at 8 and 16 mg/kg, I.P. These agents proved
to be potent elastase inhibitors in human leukocytes and J774-AI and IC-21 mouse macrophages as well as
prostaglandin cyclo-oxygenase inhibitors in J774-AI macrophages. The compounds from 5 to 50 tM
inhibited TNFot release from IC-21 macrophages and IL-1 release from mouse P388tl macrophages
induced by LPS. The binding of these cytokines to high affinity receptors on target cells, e.g. L929
fibroblasts and IL-2 in HUT78 T lymphoma cells, were also suppressed by the agents. These compounds
blocked the adhesion of leukocytes and macrophages to the plasma membranes ofL929 fibroblasts.
INTRODUCTION
Cyclic imides[1-3], -, 13- and y-alkylaminopropiophenones[4], amine-carboxyboranes and their metal
complexes[5,6], thiosemicarbazones and their metal complexes [7], and triazolidinedione derivatives[8]
have previously been shown to be potent anti-inflammatory and analgesic agents in rodents. These low
molecular weight agents like other non-steroidal anti-inflammatory agents were able to block lysosomal
hydrolytic and proteolytic enzyme activities as well as the synthesis of prostaglandins and leukotrienes,
chemical mediators of inflammation. In addition they were able to protect against free radicals generated
during inflammation. These small molecules blocked the release of cytokines synthesized by
macrophages, i.e. TNF and IL-1 and I1-6. The uniqueness of these agents is that they also competitively
displace cytokines from binding to their high affinity receptors on L929 cells. Few reports in the literature
indicate interaction at these receptor sites other than by peptides or antibodies. Suramin, a polysulfate
naphthylurea, has been shown to be an IL-6 high affinity receptor antagonist[6]. Blocking these receptors
is desirable because the entire inflammation cascade of events is triggered by the early release of TNFa
and IL-1. The therapeutic use of small molecular weight antagonists is more desirable than the use of
large molecular weight glycoproteins or growth hormones to block the inflammation or shock process.
Materials and methods
The polyphenolic-sulfonated compounds found in Table were provided as a gift by Genelabs, Inc..
Radioisotopes were obtained from New England Nuclear [Dupont, Boston, MA] and substrates and co-
factors were obtained from Sigma Chemical Co. [St. Louis, MO]. Pentosan sulfate was used as a
comparable standard in the assays and was obtained from Sigma Chemical Co.. Cell lines were obtained
from American Type Culture Collection [Rockville, MD].
In Vivo Tests
Anti-inflammatory screen in mice: Male CF male mice weighing 28-32g obtained from Jackson Lab.
[Bar Harbor, MA] were used to screen agents at 8 or 16 mg/kg intraperitoneal [I.P.] x 2 administered 3 hr
and 30 min prior to administering the irritant, according to Winter’s protocol[9,10]. Evaluation of the
induced edema was made by injecting 2% carrageenan in 0.9% saline into the plantar region of the foot.
The opposite foot injected with 0.9% isotonic saline was used as a base line. Indomethacin (8 or 10
mg/kg), pentoxifylline (50 mg/kg) and phenylbutazone (50 mg/kg) were used as standards for comparison
of activity.
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Table 1 Structures of Polyphenolic-sulfonate Compounds
n
Compound # R-- R’-- n
1 H OH 8
2 H OH 6
3 H OH 4
4 CH3 OH 8
5 CH3 ONa 4
6 CH3 ONa 6
7 OCH3 ONa 8
8 OAc ONa 8
Protection against septic shock: CF1 male mice (29-3 g) were administered lipopolysaccharides [LPS]
Salmonella abortus equi [Lot # 69F4003] [Sigma Chemical Co] at 10 mg/kg, I.P. which produced an
LDl00 within 48-52 hr that was consistent with literature values[ 11 ]. Drugs from 2 to 16 mg/kg, I.P. were
administered 2 hr prior and 2 hr post-injection of the LPS and then subsequently for every 24 hr for the
length ofthe animals’ lives. Deaths were recorded every 12 hr and continued for 96 hr. Indomethacin (8
mg/kg), dexamethasone (1 mg/kg) and pentoxyfylline (50 mg/kg) were used as standards.
In vitro TNFa and IL-1 Measurements and Cellular Regulation
IC-21 mouse macrophages were maintained in RPMI-1640 + 10% FCS + P/S. After the cells had grown
to confluency, E. coli LPS at 10 Ixg/ml was added to the medium[12,13]. Agents were incubated at 12.5 to
100M final concentration for 18 hr. The medium (100 btl) was collected for TNFCt determinations.
Interleukin- 1 [IL- 1] release was determined using P388D1 cells which were maintained in RPMI-1640 +
10% FCS + P/S. The L929 bioassay was used to quantitate the TNF and the IL-1 levels[5,6]. The L929
mouse fibroblasts were grown in DMEM + 10% FCS + P/S to confluency in 96 well plates and incubated
with 100 tl ofmedium from IC-20 or P388D cells after 18 hr. The cells were stained with 0.2% crystal
violet in 20% MeOH and read at 580 nm using a Molecular Devices scanner (SOFT-max program).
High Affinity Binding to Receptors on L929-106 Cells
Two laCi of 125I-TNFct (human recombinant, 30 mCi/tg New England Nuclear) or 125I-IL-1 (70-120[.t
Ci/lxg,New England Nuclear) was added to confluency L929 cells for 90 min or 5 hr, respectively with
25, 50 and 100 tM of the test compounds 12]. The cells were washed repeatedly with isotonic saline,
pH.7.2 and aliquots counted.
Prostaglandin cylcooxygenase activity
Mouse J774AI macrophages maintained in Dulbecco’s modified Eagle’s medium + 15% FCS + P/S. Cells
(5 x 106) were incubated with agents (5 to 100 ].tM final concentration) and 3H-arachidonic acid (100
Ci/mol) for 60 min at 37C in a CO2 incubator. The reaction was terminated with 2N HCI, the mixture
extracted 2 X with ether, and the organic layer evaporated. The residue was dissolved in ethyl acetate and
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plated on TLC silica gel plates. These were eluted with chloroform:methanol:water:acetic acid
[90:8" 1:0.8] [13,14]. The plates were developed in iodine vapor and scraped according to the Rf values of
standard prostaglandins, and counted in a Packard scintillation beta counter correcting for quenching.
Elastase Activity
The substrate N-succinyl-L-alanyl-L-alanyl-L-alanine -p-nitroanilide was used in this
assay and the hydrolytic product p-nitroanilide was determined at 410nm [15]. Porcine elastase EC
3.4.21.36 [Sigma Chemical Co.], human leukocytes or mouse macrophages were used as an enzyme
source for the assay reaction incubated from 60 min to 30 hr. Drugs were incubated from 1 to 100 laM.
Collagenase Activity
Collagenase activity was determined using Clostridium histolytricum collagenase type I, 10 g and N-
[propionate 2,3-3H]propionylated collagen incubated with agents present from to 100 lxM for 24 hr at
37C 16]. The reaction was stopped with ml 50mM EDTA and the tube centrifuged at 10,000 g for 10
in. The supematant was counted.
Cell Adhesion
RPMI 1788 leukocytes or J774 A1 mouse macrophages [108 cells] were incubated with 3H-thymidine
[New England Nuclear, 78.3 Ci/mmole] for 3 hr in growth medium 17, 18]. The cells were centrifuged
at 100 rpm for 5 min, washed in isotonic PBS, pH 7.2 and resuspended in fresh medium. Aliquots of
labelled cells were added to confluent L929 mouse fibroblasts and drugs were added from 5 to 50 tM
from 1-5 hr. The medium was decanted and L929 cells were washed repeatedly with PBS. The cells
were taken up in 0.1 N NaOH and counted.
Statistics
In all of the tables, data is calculated as 100% of control + the standard deviation. The statistical
significance was determined by the Student’s "t" test on the raw data.
RESULTS
In Vivo Pharmacology Tests
The polyphenolic-sulfonate compounds proved to be potent anti-inflammatory agents and protected
against endotoxin induced death in mice [Table 2 ]. Compounds 1-4 caused greater than 44% inhibition
of induced edema at 8 mg/kg X 2 while compounds 1, 4, 6 and $ afforded greater than 40% reduction of
edema at 16 mg/kg X 2. Compound $ was the most potent at 16 mg/kg X 2 with 62% reduction ofedema.
lndomethacin at 8 mg/kg afforded 26% reduction and at 10 mg/kg afforded 78% reduction of induced
edema. Phenylbutazone at 50 mg/kg X 2 resulted in 47% reduction in edema. In the LPS induced
endotoxin shock assay, the survival of control animals was 16% at 52 hr [Table 3]. Compounds 1, 2, 4
and $ and pentosan sulfate resulted in 83% protection from death at 16 mg/kg. Compound 3 at 8 mg/kg
and compounds 6 and 7 at 16 mg/kg resulted in 100% protection from LPS induced death. Compound 5
at 16 mg/kg resulted in 67% protection which was equal to dexamethasone at mg/kg or pentoxifylline
at 50 mg/kg.
Cytokine release and binding to high affinity receptors
TNFt release from IC-21 macrophages over an 18 hr period was significantly reduced by the agents 6, 7,
and 8 following a concentration dependent effect from 5 to 50 tM. Compounds 7 and $, achieved greater
than 50% reduction at 50 laM whereas compound 6 resulted in only 38% reduction [Table 4]. IL-1 release
from P-388Ol macrophages over 18 hr was also markedly reduced in a concentration dependent manner
with >95% reduction at 25 and 50 tM concentration of compounds 6, 7 and 8 [Table 5]. L929 TNFt
high affinity receptor binding at 90 min., the optimum time for TNFtx binding, was reduced by all three
agents with greater than 50% suppression from 12.5 to 50 lxM [Table 6]; drugs at the concentration of 25
ktM afforded the best results with >75% reduction in TNFt binding. L929 fibroblast IL-1 high affinity
receptor binding at 5 hr, the optimum time for IL-1 binding, was also reduced greater than 90% by the
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Table 2 Anti-inflammatory Activity of Polyphenolic-sulfonate Compounds
I.P. in CF Male Mice
N =6 Percent ofControl
Compound 8 mg/Kg X 2
Control O0 + 5
a
#1 51 + 4*
#2 47 + 4*
#3 58 + 6*
#4 56 + 6*
#5
#6
#7 56 + 5*
#8 70 + 6*
Pentosan polysulfate
Indomethacin 74 + 5*
Pentoxifylline
Phenylbutazone
a net increase of 84 mg edema
* p<0.001
16 mg/Kg X 2
100+ 5
56+ 5*
74+ 5*
61 +5*
48+4*
61 +5*
48+3*
72+ 5*
38+3*
49+4*
28 + 2* [10 mg/KgX 2]
70 + 6* [50 mg/Kg X 2]
[50 mg/Kg X 2]
Table 3 The Anti-Endotoxic Action of the Polyphenolic-sulfonate Compounds
in CF1 Male Mice, I.P.
N 6 Percent Survival at 52 hr
Compound 2 mg/kg 4 mg/Kg 8 mg/Kg 16 mg/Kg
Control 16 16 16 16
#1 33 50 50
#2 83 50 50 83
#3 67 50 100 50
#4 50 33 67 83
#5 33 67
#6 50 100
#7 67 67 50 100
#8 67 67 67 83
Pentosan 67 83
polysulfate
Pentoxifylline 67 + 6* [50 mg/Kg/day]
agents at 5 to 50 ktM for compounds 6 and 8 [Table 7]. Compound 7 caused greater than 80% reduction
in IL-1 binding only at 50 tM. IL-8 high affinity binding to chinese hamster ovarian carcinoma K-1 cells
was reduced-45% by compound 6 [Table 8] at 5 hr and 24 hr [Table 8]. Compounds 7, 8 and pentosan
sulfate at 50 tM caused only 21-23% reduction at 5 hr but were more effective at 24 hr txM causing >
40% reduction. IL-2 high affinity binding to HUT78 T lymphoma cell membrane receptors at 5 hr was
reduced 45% at 50 tM ofcompounds 6, 8 and pentosan sulfate. These effects were not as evident at 2 hr
but compound 8 at 50 txM caused 62% reduction of 11-2 binding and compound 7 resulted in a 31%
reduction ofI1-2 binding to its high affinity receptor [Table 9].
Enzyme Assays
Compounds 2 and 4 demonstrated potent inhibition ofJ774-A1 macrophage elastase activity at 60 min
with IC50 values of0.79 and 0.03 X 10
-5 M. Compounds 3,7 and 8 were effective with IC5o values of 1-3
X 10
-5M and all other compounds were not active at these concentrations. Incubation for 120 min
resulted in loss of elastase inhibition by the compounds with IC50 values from 2.5 to 11 X 10
-5 M at both
60 and 120 min. Human leukocyte elastase activity was inhibited similarly with IC50 values from 4.5 -28
X 10
-5M [Table 10]. Porcine elastase was inhibited at 2, 8 and 30 hr by the agnets but the IC50 values
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Table 4 TNFz Release from IC-21 Macrophages After 18 Hours Exposure to LPS
N 6 Percent ofLPS Control
Concentration tM
0
5
12.5
25
50
a 150 pg/ml
* p < 0.001
LPS Salmonella
10 ug/ml
100+6
a
Compound #6 Compound #7 Compound #8
118 + 7 113 + 5 73 + 4*
102 + 5 88+ 6 66 + 4*
86 + 6 84 + 5 44 + 3"
62 + 4* 47 + 4* 53 +4*
Table 5 Effects of Polyphenolic-sulfonates on TNFx Binding to L929 Fibroblasts
High Affinity Receptors
N 6 Percent ofControl
Concentration tM Compound #6 Compound #7 Compound #8
0 100 + 5
a 100 + 5 100 + 5
5 61 + 5* 18 + 3* 59 + 6*
12.5 39 + 4* 8 + 2* 43 / 4*
25 24 + 3 20 + 3* 23 + 4*
50 36 + 5* 17 + 3* 37 + 4*
a 12819 cpm/mg
protein* p < 0.001
Table 6 Effects of Polyphenolic-sulfonates on IL-I Release from P-388ol Cells over 18 Hours
N 6 Percent ofControl
Concentration ttM Compound #6 Compound #7 Compound #8
0 100 + 5 100 + 5 100 + 5
5 13 + 3* 71 + 6* 75+ 5*
12.5 6 + 2* 58 + 6* 66 + 4*
25 0 0 0
50 0 1+ 1" 0
a 186 ng/ml medium. * p < 0.001
Table 7 Effects of Polyphenolic-sulfonates on
125 I-IL-I High Affinity Binding to L929
Fibroblasts at 8 Hours
N 6 Percent ofControl
Concentration laM Compound # 6 Compound # 7 Compound # 8
0 100 + 6 100 + 6 100 + 6
5 3+2* 88+7 9+ 1"
12.5 3 + 2* 104 + 8 10 + 5*
25 3 + 2* 123 + 6* 9 + 5*
50 3 + 1" 18 + 8* 7 + 4*
a 16774 cpm/mg protein. * p < 0.001
were in the range of 5-9 X 10
-4 M. Clostridium histolytricum collagenase type I activity was not inhibited
significantly from 104 to 106 M concentration of drugs atter 24 hr incubation. J774-A1 prostaglandin
cyclooxygenase activity was suppressed by the agents with IC50 values of 2.06 to 7.62 X 10
-5 M [Table
10].
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Table 8 Effects of Polyphenolic-sulfonates on 12sI-IL-8 High Affinity Binding
to Chines Hamster Ovarian Carcinoma Cell K-I
N 6 Percent ofControl
Concentration tM Compound # 6 Compound # 7 Compound # 8 Pentosan
5 Hours polysulfate
0 100 + 5
a 100 + 5 100 + 5 100 + 5
50 54 + 5* 77 + 5* 79 + 4* 79 + 6*
24 Hours 100 + 6
b 100 + 6 100 + 6 100 + 6
50 65 + 7* 58 + 3* 58 + 7* 51 + 6*
100 55 + 4* 63 + 7* 51 + 6* 47 + 8*
a 190 epm, b 910 epm. *p < 0.001
Table 9 Effects of Polyphenolic-sulfonates on 12s1-11-2 High Affinity Binding to HUT-8 Cells
N 6 Percent ofControl
Concentration tM Compound #6 Compound #7 Compound #8 Pentosan
Polysulfate
2 Hours 100 + 6
a 1O0 + 6 100 + 6 O0 + 6
5 142 + 6* 165 + 7* 138 + 5* 362 + 9*
12.5 115 + 5 130 + 5* 215 + 7* 188 + 5*
25 85 + 5 119 + 6 88 + 6 123 + 7
50 81 + 4* 69 + 3* 38 + 4* 104 + 6
5 Hours 100 + 7
b 100 + 7 100 +7 100 + 7
5 100 + 6 137 + 6* 85 + 5 148 + 5*
12.5 92 + 6 100 + 7 78 + 4 89 + 6
25 78 + 5* 96 + 5 59 + 5* 81 + 6
50 55 + 4* 81 + 6 55 + 6* 55 + 4*
a 2 hours-13 cpm; b 5 hours-135 cpm/mg protein * p < 0.001
Table 10 ICs0 Values as 10"sM For Enzyme Inhibition of Polyphenolic Sulfates in Mouse
Macrophages and Human Leukoeytes
Enzyme Activity Elastase Cyclo-oxygenase
J774-A,I IC-2!,. RPMI 1788,, J744-AI
Cmp’d # 60 min 120 min 60 min 120 min 60 min 120 min 60 min
#1 NA 36 5.4 4.5 5.7 5.6 2.06
#2 0.79 24 6.7 5.7 6.7 5.7 7.62
#3 2.88 28 7.3 2.5 7.3 2.5 2.77
#4 0.03 27 5.7 5.6 5.4 4.5 5.92
#5 NA Increased 9.0 11.1 6.51
#6 NA Increased 27.5 16.2 NA
#7 1.64 Increased NA
#8 2.45 35 9.0 11.1 3.33
Pentosan NA Increased NA
poly-
sulfate
NA not active in enzyme assay
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Table 11 The Effects of Polyphenolic-suifonates on the Adhesion ofHuman
Leukocytes RPMI-1788 to Confluent L929 Fibroblasts Over Time
N 6 Percent ofControl
60 min
Control 100 + 6
a Compound #6 Compound #7
5 46 + 4* 39 + 3*
12.5 49 + 6* 35 + 5*
25 30 + 3* 40 + 4*
50 41 + 5* 49 + 4*
90 min
Control 100 + 7
b Compound #6 Compound #7
5 62 + 5* 62 + 5*
12.5 55 + 6* 55 + 5*
25 71 + 5* 65 + 5*
2 Hours
Control 100+5 Compound #6 Compound #7 Compound #8
12.5 125 + 5 108 + 7
25 100 + 6 101 + 6
50 108 + 6 104 + 8
5 Hours
Control 100+5
d Compound #6 Compound #7
12.5 92 + 4 83 + 6
25 95 + 5 92 + 5
50 88+ 7 83 + 5
92 +6
108+4
116+6
Pentosan
polysuifate
82+5
82+6
82 +.5
Compound #8
49 + 7*
40+ 5*
41 +5*
55+4
Compound #8
108+6
65 +6*
63+3*
Pentosan
polysulfate
83+5
116+6
147+6
a 5025 cpm/mg protein; b 2745 cpm/mg protein; c 360 cpm/mg protein; d 300 cpm/mg protein
* p<0.001
Table 12 The Effects of Polyphenolic sulfonates on the Adhesion ofJ-774 AI
Mouse Macrophages to Confluent L929 Fibroblasts
N 6 Percent ofControl
90 min.
Control 100+5
a Compound #6 Compound #7 Compound #8
5 137 + 6* 302 + 8* 136 + 5*
12.5 133 + 5* 196 + 6* 135 + 7*
25 128 + 7* 155 + 7* 183 + 7*
50 103 + 7* 153 + 8* 94 + 6
2 Hours
Control 100+6
b Compound #6 Compound #7 Compound #8
5 123 + 6* 123 + 5* 73 + 5*
12.5 77 + 6* 85 + 6 61 + 6*
25 118 + 7 68 + 6* 91 + 5
50 122 + 6 117 + 7 92 + 6
5 Hours
Control100+ 8 Compound #6 Compound #7 Compound #8
5 88 + 5 84 + 6 107 + 5
12.5 109 + 6 121 + 6 106 + 6
25 131 + 6* 118 + 6 125 + 7*
50 119 + 5 105 + 4 131 + 7*
a 1380 cpm/mg protein; b 1490 cpm/mg protein; c 2755 cpm/mg protein
Pentosan polysulfate
329 + 12"
363 + 16"
260 + 9*
176 +6*
Pentosan
polysulfate
75+7
53 + 6*
66+ 5*
110+6
Pentosan,
polysulfate
103+5
108+7
169+6"
187 + 7*
* P<0.001
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Cell adhesion
Compounds 6, 7, and 8 were effective from 5 to 50 tM in reducing significantly the adhesion ofhuman
leukocytes to confluent L929 fibroblasts at 60 and 90 min but were not effective at 2 and 5 hr [Table 11 ].
The agents were not as effective in reducing J774A1 macrophage adhesion to L929 fibroblasts at these
concentrations [Table 12]. At 2 hr at 12.5 tM, they caused 15% to 39% reduction, yet pentosan
polysulfate caused 47% reduction at 12.5 tM.
DISCUSSION
A number of small molecular weight agents, e.g. amine-carboxyboranes and their metal complexes,
indazolones, 3-imino-1-oxoisoindolines, triazolidinedione derivatives, ix, 1, and y alkylaminoketones, and
thiosemicarbazones as well as their metal complexes afforded similar reductions in induced edema as the
polyphenolic sulfonates. These non-steroidal anti-inflammatory agents suppress both TNFtz and IL-1
release and cytokine receptor binding from 25 to 100 tM similar to the current polyphenolic sulfonates.
These agents as well as the polyphenolic sulfonates were very effective in protecting against LPS induced
shock. Shock is mediated by the release of these regulatory cytokines, i.e TNFtx and IL-1 and their
binding to receptors on target inflammation cells which causes the release of inflammation enzymes and
chemical mediators as well as enhancing adhesion of inflammatory cells to tissue lesions. It is difficult to
determine whether the effects of the agents are direct or indirect in acting as antagonists of high affinity
receptors for cytokine regulation, but they did effectively block elastase and cyclooxygenase activities and
cell adhesion. The cytokines, e.g. TNFtx, are large glycoproteins which exist as a trimer, folding so that
only three small regions interact with specific high cysteine regions of the high affinity receptors.
Mutagenic studies have indicated that only a few amino acid residues are important to binding of TNFtt.
The oligosaccharides of the cytokine molecule are thought to play a role in the binding of the cytokine to
its receptor, since alterations of their structural composition leads to decreased binding of the cytokine
molecule to the high affinity receptors. Sulfamoylthiophenone and sulfamoylpyrazole carboxylic acid
derivatives have recently been shown to be anti-inflammatory and analgesic agents [19]. Thus, the
polyphenolic sulfonates may play a similar role at these receptor binding sites, competing with the
endogenous cytokines. Since TNF regulates IL-1, IL-6 and IL-8 as well as its own release, there is a
possible cross-over in the effects of agents on the cytokine receptors. More than one receptor exists on
cells for some of the cytokines, i.e. TNFtx and IL-1. What is most significant concerning these findings is
that it may be possible to modulate cytokine effects on metabolism, proliferation, immunomodulation, etc.,
without using a large molecular weight protein that has deleterious side effects such as allergy and
anaphaxisis. Numerous small molecular weight agents such as flavones, thalidomide, cyclosporin A,
methotrexate, dexamethasone, or pentoxifylline, block TNFo or I1-1 synthesis or release from
macrophages. Tenidap, which has structural features similar to the cyclic imides, appears to effect both I1-
and TNFtx production and activation from human monocytes. All of the anti-inflammatory and anti-
rheumatoid agents found to date require in vivo doses 3-50 mg/kg, yet the studies in tissue culture to
block cytokine synthesis and release require IC50 values in the 0.2 to 0.5 mM range, i.e. IC50 value for
pentamidine is 1 mM, IX 207-887 is 30-60 mM and hydrocortisone is 10 mM. The drug RP 54-745
decreases mRNA synthesis of both TNFct and IL-1 atter challenge with LPS. It is active in vivo at 25
mg/kg in mice but in vitro studies required 3 10 mM concentrations. Thus, the effect of polyphenolic
sulfonate follows a similar pattem to other small molecular weight agents on cytokine modulation of the
inflammation process. Because of these observations further investigation into their properties as
potential therapeutic agents is needed.
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